References
- Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465.
- Nazha A, Narkhede M, Radivoyevitch T, et al. Incorporation of molecular data into the revised international prognostic scoring system in treated patients with myelodysplastic syndromes. Leukemia. 2016;30:2214–2220.
- Bernard E TH, Greenberg PL, Hasserjian RP, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM EVID. 2022;1:1–14.
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–1719.
- Ferrone C, Wong H, Semenuk L, et al. Validation and clinical impact of the Oncomine myeloid targeted DNA and RNA ion semiconductor sequencing assay. Blood. 2018;132:5523.
- Atli EI, Gurkan H, Atli E, et al. The importance of targeted next-generation sequencing usage in cytogenetically Normal myeloid malignancies. Mediterr J Hematol Infect Dis. 2021;13:e2021013.
- Greenberg PL, Stone RM, Al-Kali A, et al. NCCN guidelines(R) insights: myelodysplastic syndromes, version 3. 2022. J Natl Compr Canc Netw. 2022;20:106–117.
- Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–3627; quiz 99.
- Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–1089.